",,hummmmm,,,,,,,did DM not tell us that patients in this trial asked to remain on 208 even after their dosing time was met,,,,,,,,,,,,,,,,,,,can we read anything into this??....should we?,,,I dont understand why any individual would have requested an extension in such a trial unless something physical improved for the person,,,,and we were also told everyone wanted to stay on it!"

The BETonMACE trial protocol was amended to allow ALL patients to continue dosing past the previous 104 week limit. Patients and investigators remained blinded. Both placebo and apabetalone groups continued dosing past 104 weeks. There is no evidence that this extension was at the request of the patient. It was a trial amendment initiated by Resverlogix and the investigators, likely to accumulate more patient years and safety data. I would not read too much into this.

BearDownAZ